Notch Signaling Pathway Blocked by γ-secretase Inhibitor and Its Effect on the Growth and Apoptosis of SKOV3 Cells

LU Yu-li, XIE Cheng

Abstract

To determine the effect and mechanism of γ-secretase inhibitor DAPT on the growth and apoptosis of human ovarian carcinoma SKOV3 cells. Methods The effect of γ-secretase inhibitor DAPT was tested in vitro using SKOV3 cells. Its inhibition effect on cell proliferation was determined by CCK-8 assay. The cell apoptosis was detected by AO/EB double staining and flow cytometry. The expression of Notch1 mRNA and protein was detected by RT-PCR and Western blot. Results Compared with controls, 5 μmol/L, 10 μmol/L and 20 μmol/L of DAPT showed an effect of cell growth inhibition in a dose-dependent manner, with 19.87%, 28.38%, and 46.67% of 24 h inhibitory rates, respectively. Dose-dependent effect of DAPT on cell apoptosis was also evident, with (5.80 ± 0.98)%, (12.96 ± 4.99)%, (30.88 ± 7.63)%, and (42.98 ± 1.46)% apoptosis rates for the control, 5 μmol/L, 10 μmol/L and 20 μmol/L DAPT groups, respectively. RT-PCR analysis demonstrated that the expression of Notch1 mRNA decreased significantly in the DAPT groups, with an inhibition rate of 10.23%, 20.50%, and 38.83% for the three DAPT groups, respectively. Western blot results demonstrated that the expression of Notch1 protein decreased significantly, with an inhibition rate of 12.89%, 27.47%, and 49.84% for the three DAPT groups, respectively. Conclusion γ-secretase inhibitor DAPT can block Notch signaling pathway, inhibit proliferation, and induce apoptosis of SKOV3 cells through down-regulation of the expression of Notch1.

 

Keywords: γ-secretase inhibitor, Proliferation, Apoptosis, Notch signaling pathway 

 

 

Full Text:

PDF


References


Multi-center evaluation of post-operative morbidity and mortality after optimal cytoreductive surgery for advanced ovarian cancer. PLoS One, 2012; 7( 7); e39415. doi; 10.1371/ journal, pone. 0039415. Epub 2012 Jul 23.

Heitz F, Harter P. Barinoff J. et al. Bevacizumab in the treatment of ovarian cancer. Adv Ther, 2012; 29 (9): 723-735. doi; 10. 1007/sl2325-012-0041-9. Epub 2012 Aug 21.

Shao H. Huang Q. Liu ZJ. Targeting Notch signaling for cancer therapeutic intervention. Adv Pharmacol,2012;65 ; 191- 234. doi: 10. 1016/B978-0-12-397927-8. 00007-5.

Purow B. Notch inhibition as a promising new approach to cancer therapy. Adv Exp Med Biol. 2012; 727: 305-319. doi: 10. 1007/978-1-4 614-0899-4_23.

Wang J. Wang С, Meng Q, et al, siRNA targeting Notch-1 decreases glioma stem cell proliferation and tumor growth. Mol Biol Rep. 2012; 39(3): 2497-2503.

Yoo CB. Yun SM. Jo С, et al. y-Secretase-dependent cleavage of E-cadherin by staurosporine in

Yu S. Zhang R, Liu F, et al. Down-regulation of Notch signaling by a y-secretase inhibitor enhances the radiosensitivity of nasopharyngeal carcinoma cells. Oncol Rep, 2011;26(5):1323-1328.

Han J, Ma I. Hendzel MJ, et al. The cytotoxicity of ugamma- secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition. Breast Cancer Res,2009; 11 (4): R57. doi; 10. 1186/bcr2347. Epub 2009 Aug 6.

van Es JH, van Gijn ME, Riccio O, et al. Notch/gamma- secretase inhibition turns proliferative cells in intestinalcrypts and adenomas into goblet cells. Nature, 2005; 435 ( 7044 ): 959- 963.

Haveman J, Bergs JWJ, Franken NAP, et al. Effect of hyperthermia on uptake and cytotoxicity of cisplatin in cultured murine mammary carcinoma cells. Oncol Rep. 2005; 14 (2) ; 561-567.

Istomin YP, Zhavrid EA, Sachivko NV, et al. The effect of cytostatics and hyperthermia on RAJI human lymphoma cells. Exp Oncol,2011;33:19-23.

Istomin YP. Zhavrid EA. Alexandrova EN. et al. Dose enhancement effect of anticaner drugs associated with increased temperature in vitro. Exp Oncol. 2008; 30( 1): 56-59.

Almeida GM. Duarte TL, Farmer PB, et al. Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model; implications for predictive testing. Int J Cancer.2008; 122(8): 1810-1819.

Krivak TC, Darcy KM, Tian C, et al. Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study. Gynecol Oncol, 2011; 122(1 ): 121- 126.

Moxley KM, Benbrook DM, Queimado L. et al. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer. Gynecol Oncol,2013; 130(2) ;377-382.


Refbacks

  • There are currently no refbacks.